Associations Between Adrenal Insufficiency and Cardiovascular Outcomes in Patients Hospitalized with Takotsubo Cardiomyopathy: Insights from the Nationwide Readmissions Database (2019)

Read full text
Authors: N. Ben Abdallah, Nihar Kanta Jena, Gisha Mohan, Sreekant Avula
Cited by: 0
References: 14

Abstract

Background/Objectives: Patients with adrenal insufficiency (AI) are at an increased risk of adverse events (AEs) during cardiovascular hospitalization. However, the association between AI and takotsubo cardiomyopathy (TCM) remains unclear. We investigated the association between AI and cardiovascular outcomes in patients with TCM. Methods: We analyzed data on patients with TCM included in the 2019 Nationwide Readmissions Database to compare in-hospital outcomes between patients with and without AI. The primary outcome measure was inpatient mortality. Secondary outcomes included the odds of all-cause 90-day readmission, acute kidney injury (AKI), mechanical ventilation use, vasopressor use, cardiogenic shock, length of stay (LOS), and total hospitalization charges (THC). Multivariate regression models were used to adjust for confounding variables. Results: Among 30,987 cases, 0.59% (n = 183) had concomitant AI. AI was associated with higher odds of in-hospital mortality (adjusted odds ratio [aOR] 3.32, 95% confidence interval [CI] 1.43–7.74, p = 0.005), cardiogenic shock (aOR 5.28, 95% CI 3.16–8.82, p < 0.001), mechanical ventilation use (aOR 3.20, 95% CI 1.78–5.74, p < 0.001), AKI (aOR 1.96, 95% CI 1.11–3.48, p = 0.021), vasopressor use (aOR 4.59, 95% CI 1.56–13.47, p = 0.006), longer LOS (6.84 vs. 3.67 days, p < 0.001), and higher THC ($97,419 vs. $54,574, p < 0.001). Additionally, AI was associated with lower odds of all-cause 90-day readmissions (aOR 0.44, 95% CI 0.25–0.79, p = 0.006). Conclusions: Among patients with TCM, AI was associated with higher odds of fatal and non-fatal adverse events. Further studies are required to confirm these findings and better understand how to improve outcomes in this high-risk population.

Fields of Study & Subjects

Adrenal and Paraganglionic Tumors Adrenal Hormones and Disorders Hormonal Regulation and Hypertension

Publication details

Journal / source
Endocrines
Volume
7
Issue
2
Pages
16–16
Publication date
20 April 2026
Language
EN